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Meticillin-resistant Staphylococcus aureus (MRSA) 
disseminates between hospitals serving one patient 
catchment area. Successful prevention and control 
requires concerted efforts and regional surveillance. 
Forty hospitals located in the German EUREGIO have 
established a network for combating MRSA. In 2007 
they agreed upon a synchronised strategy for screen-
ing of risk patients and a standard for transmission-
based precautions (search and follow). The same year, 
the hospitals started synchronised MRSA prevention 
and annually reporting MRSA-data to the public health 
authorities. The median rate of screening cultures per 
100 patients admitted increased from 4.38 in 2007 
to 34.4 in 2011 (p<0.0001). Between 2007 and 2011, 
the overall incidence density of MRSA (0.87 MRSA 
cases/1,000 patient days vs 1.54; p<0.0001) increased 
significantly. In contrast, both the incidence density 
of nosocomial MRSA cases (0.13 nosocomial MRSA 
cases/1,000 patient days in 2009 vs 0.08 in 2011; 
p=0.0084) and the MRSA-days-associated nosocomial 
MRSA rate (5.51 nosocomial MRSA cases/1,000 MRSA 
days in 2009 vs 3.80 in 2011; p=0.0437) decreased 
significantly after the second year of the project. We 
documented adherence to the regional screening strat-
egy resulting in improved detection of MRSA carriers 
at admission. Subsequently, after two years the noso-
comial MRSA-incidence density was reduced. Regional 
surveillance data, annually provided as benchmarking 
to the regional hospitals and public health authorities, 
indicated successful prevention.
Introduction
Meticillin-resistant Staphylococcus aureus (MRSA) glob-
ally belongs to the most frequent causes of healthcare-
associated infections [1]. In addition, the severity of 
MRSA infections is documented by studies estimating 
that patients with MRSA bloodstream infection (BSI) 
have a higher 30-day mortality compared to those with 
BSI due to meticillin-susceptible S. aureus (MSSA) [2].
In 2007, the annual burden of MRSA infections in 
European Union (EU) Member States, Iceland and 
Norway was estimated to comprise 171,200 cases 
including 12% BSI [3]. However, MRSA rates in Europe 
show remarkable differences: In 2010, Sweden 
reported the lowest proportion of invasive isolates 
resistant to meticillin (0.5% of all S. aureus) and 
Portugal the highest (52.2%) [4]. Such discrepancies 
were even reported when comparing directly neigh-
bouring countries. In the German federal state of North 
Rhine-Westphalia (NRW), 57.6 MRSA bacteraemia epi-
sodes per 1,000,000 inhabitants were reported to 
public health authorities in 2010, whereas only a few 
kilometres across the Dutch–German border the rate 
of bacteraemia episodes was estimated to be 1.8 per 
1,000,000 inhabitants in the Netherlands [5,6]. Hence, 
the prevalence of MRSA differs nationally and region-
ally. Moreover, it was found that there are substantial 
regional differences regarding the molecular subtypes 
of MRSA circulating in Europe [7] and that compared 
with other continents, which observed a shift of the 
major MRSA burden from healthcare institutions into 
the community, healthcare-associated (HA-) MRSA are 
still predominant in Europe [8].
The molecular epidemiology of MRSA in Europe indi-
cates that the dissemination of MRSA is mainly gov-
erned either by direct transfer of patients between 
hospitals, nursing homes and other healthcare facili-
ties or by indirect exchange of patients admitted con-
secutively to several facilities in one same catchment 
area [7]. Indeed, of 354 MRSA carriers identified at 
admission to German hospitals, 32 were directly trans-
ferred from other hospitals, 173 had been hospital-
ised for > 24 h in the previous six months and 58 were 
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residents of long-term care facilities [9]. Other studies 
have shown that patients once identified as MRSA car-
riers had a 44% probability of being re-admitted to the 
same or other regional hospitals whilst still carrying 
MRSA [10] and that of 1,032 known patients with pre-
vious MRSA carriage attending the Hannover Medical 
School hospital, 39% were re-admitted more than once 
during a 46-month period, 59% of which remained 
MRSA positive during all admissions [11]. Simulating 
the importance of inter-facility patient movements, it 
has been shown that especially small long-term care 
facilities with low patient turnover rates are most sus-
ceptible to sustaining high MRSA prevalence, espe-
cially when cooperating with large, high-prevalence 
hospitals [12]. A model based on patient-flow char-
acteristics of 29 acute care hospitals cooperating in 
Orange County, California, revealed that in case of an 
outbreak (increase of MRSA prevalence to 15%) in a 
single hospital within the county, most other regional 
hospitals also experienced an increase of the MRSA 
prevalence (median increase of MRSA prevalence 
1.8%). In this model, even outbreaks in single intensive 
care units affected the overall prevalence of MRSA in 
regional acute care hospitals [13].
In consequence, the referral of patients between 
regional hospitals might contribute to MRSA spread. 
Thus preventive standards for MRSA control imple-
mented only locally in single hospitals may be not 
effective to reduce MRSA. The implementation of har-
monised preventive standards in the regional health-
care cluster, where the nosocomial pathogen spreads 
predominantly is more likely to be successful. The hos-
pitals of the Dutch–German border region EUREGIO have 
been confirmed to represent such a regional healthcare 
cluster using mathematical modelling [14]. Therefore, 
the governments of the 16 German Bundesländer (i.e. 
federal states) have recommended to address the 
problem of antimicrobial resistance in regional net-
works of hospitals and other institutions involved in 
patient care [15], and to apply regional approaches and 
concerted regional action to solve the MRSA problem 
[15,16]. In addition, the implementation of preven-
tive interventions including screening of defined risk 
patients, single or cohort room isolation and the use of 
transmission-based precautions (gloves, gowns) when 
caring for MRSA colonised or infected patients [17,18] 
has been recommended for all German acute care hos-
pitals. However, despite the availability of guidance 
[19], it was shown that for German hospitals it is chal-
lenging to implement preventive bundles sufficiently 
and in a standardised manner on a local and regional 
level [20]. To reinforce regional cooperation and over-
come the problem of limited local implementation, all 
40 hospitals in the Münsterland region in NRW are 
cooperating in the EU-funded Dutch–German EUREGIO 
MRSA-net (www.mrsa-net.eu) and EurSafety Health-
Net (www.eursafety.eu) projects since 2005. Since 
these 40 hospitals form a connected healthcare cluster 
[14], and contain all hospitals in the region, they can 
be considered to form a single patient catchment area. 
In 2007, hospitals agreed upon and started the imple-
mentation of a concerted strategy for identification of 
MRSA carriers by (pre)admission MRSA screening of 
risk patients, isolation of carriers, continued care and 
decolonisation even after transfer to another hospital 
or after discharge and collection of basic MRSA surveil-
lance data for centralised analysis and benchmarking 
[9,15]. In this report, we analyse surveillance data col-
lected between 2007 and 2011 resulting from the net-
work with respect to changes in the implementation 
of MRSA screening and the number and incidences of 
imported and nosocomial MRSA cases.
Methods
The German part of the project region geographically 
comprises six German districts (codes DEA33, DEA34, 
DEA35, DEA37, DEA38 and DE94B, level3, according 
to the Nomenclature of Territorial Units for Statistics) 
[21] and is inhabited by 1.7 million people. In 2007, 40 
hospitals were located in the region, treating about 
360,000 patient cases during 2,500,000 inpatient days 
per year. Of 40 hospitals, 36 were acute care hospitals, 
while one was a rehabilitation clinic and three hospi-
tals were specialised in psychiatry.
During a prevalence screening of all admissions and 
risk factor assessment in November 2006, 35.6% 
of patients admitted to the hospital had at least one 
MRSA risk factor [9]. In 2007, all hospitals started to 
systematically screen defined patients associated with 
any one of the known risk factors described previously 
[9], prior to or at admission to hospital. In 2008, the 
risk factors were slightly adapted according to a new 
German national recommendation [18]. In the project 
there was no harmonised microbiological protocol 
for performing the MRSA screening. Mostly a culture-
based approach using chromogenic MRSA media was 
used. Positive screening was followed in all hospitals 
by the implementation of single or cohort room isola-
tion, transmission-based precautions and decoloni-
sation therapies as recommended in Germany [17]. 
Adherence to the recommendations was checked 
exemplarily by the local public health authorities dur-
ing annual inspections.
Since 2007 standardised MRSA-related data were col-
lected, based on a surveillance protocol adapted from 
that of the national German Nosocomial Infections 
Surveillance System to ensure comparability [22]. We 
analysed and reported all surveillance results and 
reported once a year to the participating hospitals in 
an anonymised feedback data set via the responsible 
public health offices.
Data collection
The collected surveillance data included the numbers 
of MRSA cases (colonisation and infection) classified 
as imported or nosocomial cases, the overall number of 
patient cases treated and the overall number of patient 
days as well as patient days of MRSA cases and the 
number of nasal swabs performed at admission. The 
3www.eurosurveillance.org
findings of at least each MRSA-detection based on the 
first positive isolates of all MRSA-inpatient cases were 
inserted in a database (Epi-MRSA®, Ridom GmbH, 
Münster, Germany or Excel®, Microsoft Inc., Redmond, 
USA). For each case, information on every first MRSA 
isolate was included in an annual report to the pub-
lic health authorities with one exception: if a patient 
developed a MRSA bacteraemia during the hospital 
stay, this detection of MRSA-bacteraemia based on the 
positive MRSA blood culture isolate was included in the 
report. Each MRSA-detection (colonisation or infection) 
of isolates sampled more than three days after admis-
sion was classified as nosocomial unless the patient 
was a known MRSA carrier. A day, which an MRSA 
patient spent in hospital, was classified as MRSA-in-
hospital day. In most hospitals, the MRSA-in-hospital 
days could be specified by counting the isolation days 
of MRSA cases.
Data analysis
We analysed the surveillance data of five years (2007–
2011) and calculated the following parameters: (i) 
number of MRSA cases, classified as imported or noso-
comial cases, (ii) screening rate (number of screen-
ing cultures/100 admissions), (iii) MRSA incidence 
at admission (imported MRSA cases/100 admitted 
cases), (iv) MRSA incidence density (MRSA cases/1,000 
patient days), (v) nosocomial MRSA incidence density 
(nosocomial MRSA-cases/1,000 patient days), (vi) the 
mean daily MRSA-burden (MRSA-in-hospital days/100 
patient days), (vii) MRSA-days-associated nosoco-
mial MRSA rate (nosocomial MRSA-cases/1,000 MRSA 
days).
Time trends of MRSA parameters were analysed by 
Friedmann test (p<0.05 was considered significant). 
The percentage of nosocomial MRSA cases on all MRSA 
cases was assessed by Cochran Armitage test of lin-
ear trend (p<0.05). The correlation of MRSA parameters 
was done calculating the Spearman rank correlation 
coefficient (p<0.05). All statistical analyses were done 
using SAS 9.2 software (SAS Institute Inc., Cary, USA). 
Results of significance tests were discarded if the pro-
gramme displayed an alert due to more than 10% of 
missing values in the respective dataset.
Results
In this study, we collected MRSA-related data of 
regional hospitals in the EUREGIO during a five-year 
period. While in 2007 and 2008, 38/40 hospitals (95%) 
participated in surveillance, the participation rate was 
100% in 2009 (40/40 hospitals), 2010 (38/38 hospitals) 
and 2011 (37/37 hospitals). The number of participating 
hospitals changed from 40 to 37 because of acute care 
hospital fusions.
Overall, the implementation of the screening strat-
egy as monitored by analysis of the median screening 
rate increased significantly (p<0.001) over time from 
4.38/100 patients (interquartile range (IQR): 2.15–11.8) 
admitted in 2007 to 34.4/100 patients (IQR: 27.4–51.6) 
in 2011 (Table 1, Figure 1).
Table 2 shows the numbers of documented regional 
MRSA cases. In 2007, the total number of cases was 
2,351. For 1,864 of these cases stratification into 
imported (1,481) and nosocomial (383) cases was pos-
sible (Table 2). Between 2007 and 2011, the overall 
number of cases increased significantly (p<0.0001). 
According to Cochran Armitage trend test, the percent-
ages of imported cases on all MRSA cases increased 
significantly (p<0.0001) between 2007 and 2011, while 
the percentage of nosocomial cases on all MRSA cases 
decreased significantly (p<0.0001) (Table 2).
From 2007 to 2011, the MRSA admission incidence (0.51 
vs 1.09 MRSA cases/100 patients admitted), the MRSA-
incidence density (0.87 vs 1.54 MRSA cases/1,000 
patient days) as well as the mean daily MRSA-burden 
(1.30 vs 1.82 MRSA-in-hospital days/100 patient days) 
increased significantly (p<0.0001) (Table 1). These 
overall increases were due to increases in the years 
from 2007 to 2009. From 2009 to 2011, the MRSA 
admission incidence (p=0.5796), the MRSA incidence 
density (p=0.6729) and the mean daily MRSA-burden 
(p=0.7327) remained stable.
The incidence density of nosocomial cases decreased 
from 0.14 nosocomial MRSA cases per 1,000 patient 
days in 2007 to 0.08 per 1,000 patient days in 2011 
Figure 1
Distribution of increasing screening rate at admission to 
identify meticillin-resistant Staphylococcus aureus (MRSA) 
carriers in German regional hospitals of the EUREGIO, 
2007–2011 (n=40)
IQR: interquartile range. 
Distribution of nasopharyngeal admission screening cultures per 
100 patients admitted to the 40 German hospitals of the EUREGIO 
taking part in a concerted strategy for identification of MRSA 
carriers. For each year the number of screenings per 100 patients 
is shown in the boxplot with whiskers as minimum and maximum 
and outliers as squares below 1.5*IQR*25th percentile or above 
1.5*IQR*75th percentile and far outliers above 3*IQR*75th percentile. 
50% of hospitals reported a screening rate indicated in the 
rectangle with the mean (plus) and the median (band).
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(Table 1). The MRSA-days-associated nosocomial MRSA 
rate decreased from 9.52 nosocomial MRSA cases per 
1,000 MRSA days in 2007 to 8.14 in 2008 and to 5.51 
in 2009. It subsequently increased to 7.77 in 2010 fol-
lowed by a decrease to 3.80 in 2011 (Table 1).
The data quality allowed for specifying the significance 
of trend for these parameters from 2009 to 2011 only; 
other time periods were statistically excluded for lack 
of more than 10% of the data. From 2009 to 2011, the 
MRSA-admission incidence remained stable (p=0.5796) 
whereas the nosocomial MRSA-incidence density 
(p=0.0084) as well as the MRSA-days-associated noso-
comial MRSA rate (p=0.0437) decreased significantly.
There was a moderate positive correlation between 
the mean daily MRSA-burden and the screening rate 
(Spearman rank correlation coefficient r=0.32710; 
p<0.0001) (Figure 2). Furthermore, there was a low neg-
ative correlation between the MRSA-days-associated 
nosocomial MRSA rate and the screening rate 
(Spearman rank correlation coefficient r=-0.23829; 
p=0.0017) (Figure 3). In Figures 2 and 3, the median and 
the IQR are plotted. In this way, hospitals beyond the 
50% range may be graphically detected, stimulating 
inspection and, if necessary, intervention measures.
Discussion
According to the antimicrobial resistance surveillance 
in Europe in 2010, MRSA is the most important cause 
of antibiotic resistant healthcare-associated infections 
worldwide. In 11 of 28 European countries, the per-
centage MRSA-isolates per S. aureus-isolates in blood 
cultures is higher than in Germany. The S. aureus resist-
ance to meticillin in Germany in 2010 is still reported 
as increasing [4].
Due to an active search and destroy policy in Dutch 
hospitals, the incidence of hospital-associated cases 
and the rate of nosocomial transmission have been 
kept at a low level since decades [23]. Within the 
framework of two Dutch–German preventive network 
projects (EUREGIO MRSA-net and EurSafety Health-
net), we aimed to establish an adapted ‘search and 
follow’ strategy in hospitals in the German part of the 
Dutch–German border area [24]. This includes active 
search by region-wide screening for MRSA carriage at 
admission following the standardised implementation 
Table 2
Numbers of meticillin-resistant Staphylococcus aureus cases documented in 40 German hospitals in the EUREGIO, 
2007–2011
Numbers of MRSA cases
2007 2008 2009 2010 2011
n (%) n (%) n (%) n (%) n (%)
MRSA (total) 2,351 (100) 3,522 (100) 4,206 (100) 4,276 (100) 4,512 (100)
MRSA (stratified)a 1,864 (100) 3,263 (100) 3,759 (100) 4,150 (100) 4,347 (100)
     Imported MRSA cases 1,481 (79) 2,807 (86) 3,262 (87) 3,641 (88) 3,992 (92)
     Nosocomial MRSA cases 383 (21) 456 (14) 497 (13) 509 (12) 355 (8)
MRSA: meticillin-resistant Staphylococcus aureus.
a Number of MRSA cases with available information allowing stratification as imported or nosocomial.
Table 1
Admission screening rates and meticillin-resistant Staphylococcus aureus related rates in 40 hospitals in the EUREGIO, 
2007–2011
Parameter
2007 2008 2009 2010 2011
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
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of transmission-based precautions (hand hygiene, iso-
lation and contact precaution) and decolonisation of 
MRSA carrier.
Here we present surveillance data obtained from this 
regional network aiming to prevent inter-institutional 
MRSA spread. We demonstrate that the network struc-
tures enabled the implementation of a risk-based 
admission screening approach. This was documented 
by a significant increase of nasopharyngeal MRSA 
screenings performed in the network hospitals after 
agreement upon a minimum standard for a screen-
ing regime. The aim of the network was to establish 
a screening of patients at a higher risk of MRSA car-
riage as defined by national German recommenda-
tions [17,18]. In 2011, the regional hospitals achieved 
a median screening rate of about 30%, which argues 
for successful implementation of the screening-policy. 
The latter is supported by the study in which the same 
hospitals have assessed risk factors for MRSA carriage 
among all patients admitted during a one-month period 
in 2006. A total of 35.6% of the patients exhibited at 
least one risk factor at admission. The observed admis-
sion MRSA prevalence was 1.6/100 patients [9].
The effect of the improved admission screening was 
demonstrated by an overall 92% increase of MRSA 
cases detected in the participating hospitals. Moreover, 
the MRSA admission-incidence nearly doubled (0.51 
MRSA/100 patients in 2007 vs 1.09 MRSA/100 patients 
in 2011). This increase was not surprising as it is known 
that 69 to 85% of all MRSA cases are not detected if 
microbiological cultures are only performed for clinical 
reasons and screening is not implemented [25].
We assume that the risk-based screening strategy 
implemented in the participating hospitals still does 
not detect all MRSA cases, but, according to our data 
at least 68%, due to the observed admission-incidence 
after full implementation (1.09/100 patients) which is 
Figure 2
Moderate positive correlation between the mean daily meticillin-resistant Staphylococcus aureus burden and the screening 
rate, stratified by screening extent, of 40 German regional hospitals, EUREGIO, 2007–2011
MRSA: meticillin-resistant Staphylococcus aureus.
Moderate positive correlation between mean daily MRSA burden (MRSA-in-hospital days/100 patient days) and screening rate (admission 
screenings/100 patients). Each sign represents a network hospital once a year from 2007 to 2011, with the respective colour and shape 
reflecting the degree of screening implementation in nasal swabs per 1,000 patient days. The grey lines represent the respective medians and 
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lower than the admission burden found when screening 
all regional patients at admission (1.6 MRSA cases/100 
patients) [9].
Furthermore in 2011, the MRSA admission incidence 
was higher compared to the median incidence of 0.83 
MRSA/100 patients described in 302 of 2,041 German 
hospitals participating in a German nationwide sur-
veillance programme [22,26]. Since data from admis-
sion prevalence screening studies do not indicate that 
MRSA was more endemic in the EUREGIO compared to 
other parts of Germany [27], this difference is most 
likely due to the fact that the median screening rate 
was 34.4/100 patients in the EUREGIO-hospitals, but 
much lower (9.39/100 patients) in hospitals taking part 
in the national surveillance programme. However, from 
2009 to 2011, we observed a stabilisation of the MRSA-
incidence and the mean daily MRSA burden, which 
indicates a saturation of excess MRSA detection due to 
enhanced screening.
The improved detection of MRSA at admission also led 
to a decrease in the proportion of nosocomial MRSA-
cases within all MRSA cases. This is similar to results 
reported by other authors for 26 hospitals involved 
in the German nationwide MRSA surveillance from 
2004 to 2006 [28], but has so far not been shown in 
a region-wide surveillance. From 2004 to 2009, the 
111 hospitals, taking continuously part in the German 
national MRSA surveillance, reported a stable nosoco-
mial MRSA incidence density of about 0.25 nosocomial 
MRSA cases per 1,000 patient days. A decrease was 
only observed in intensive care units [29]. The EUREGIO 
hospitals reported from 2007 to 2009 about 0.14 noso-
comial MRSA cases per 1,000 patient days and even a 
significant reduction from 2009 to 2011.
The time-delayed reduction of nosocomial MRSA inci-
dence density may be because the improved screen-
ing leads stepwise to better detection of MRSA cases 
in general, increasingly allowing better containment 
Figure 3
Low negative correlation between the meticillin-resistant Staphylococcus aureus (MRSA)-days-associated nosocomial MRSA-
rate and the screening rate, stratified by screening extent, of 40 German regional hospitals, EUREGIO, 2008–2011
Low negative correlation between the MRSA-days-associated nosocomial MRSA-rate (number of nosocomial MRSA-cases/1,000 MRSA-patient-
days) and screening rate (admission screenings/100 patients). Each sign represents a network hospital once a year from 2007 to 2011, with 
colour and shape reflecting the degree of screening implementation in nasal swabs per 1,000 patient days. The grey lines represent the 
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of the bacteria and more limiting spread in the hospi-
tal by MRSA-management measures like for example 
hand hygiene, contact precautions, and decolonisa-
tion efforts. The introduction of screening at admission 
and the increased awareness for MRSA in the hospitals 
might have led to more detection of nosocomial MRSA-
cases as well as to fewer MRSA cases not classifiable 
as imported or nosocomial (21% in 2007 vs 4% in 2011). 
On the other hand, there might be less ‘false’ nosoco-
mial MRSA-cases (imported MRSA-cases detected via 
an isolate sampled from an inpatient after three days 
of hospital stay). Additionally, it may be that the hos-
pitals improved the quality of the submitted data at 
least from 2009 to 2011, after two years of participa-
tion in the surveillance system. Furthermore the noso-
comial MRSA incidence density was low (about 0.14 
MRSA cases/1,000 patient days) in the 40 EUREGIO-
hospitals compared to 111 hospitals, which took part 
in the German national surveillance system (0.25 MRSA 
cases/1,000 patient days, stable from 2004 to 2009). 
The low number MRSA cases per 1,000 patient days in 
our hospitals reduced the probability for a (significant) 
decrease, which we could nevertheless demonstrate 
from 2009 to 2011.
For infection control staff, the advantage of improved 
MRSA detection at admission is that detection of noso-
comial cases more reliably reflects cases of MRSA 
infection or colonisation which are caused by intra-
institutional transmission of the pathogen. This is 
important because a high number of nosocomial MRSA 
cases per 1,000 patient days (i.e. a nosocomial MRSA-
incidence in the range of the upper quartile of all hos-
pitals taking part in a surveillance system) might be 
an indicator for deficits in infection control and/or for 
selection pressure due to use of antibiotics, which 
should be checked for possible improvements [30]. 
Locally, the knowledge of nosocomial MRSA cases 
enables more targeted reactions with respect to elu-
cidating the transmission pathways and implementing 
measures appropriate to forestall further transmission.
Admission screening for MRSA carriage has been 
shown to be (cost-) effective in reducing both nosoco-
mial infections and MRSA transmission on the wards, 
because it enables timely implementation of transmis-
sion-based precautions, isolation and decolonisation 
therapies [31,32]. Although, we did not assess to what 
extent isolation measures or decolonisation thera-
pies were performed for the MRSA patients detected, 
applying a standardised panel of MRSA infection con-
trol measures in all participating hospitals was part of 
the network’s quality goals and the implementation 
of these measures was controlled exemplarily by the 
regional public health authorities. Since nosocomial 
transmission is more probable in a hospital with a high 
mean daily MRSA burden than in a hospital with a low 
mean daily MRSA burden, the MRSA-days-associated 
nosocomial MRSA rate is used to compare hospitals 
as this rate takes into account the institutional mean 
daily MRSA-burden and thereby reflects the degree 
of transmission on the ward more reliably [33]. In this 
study, we observed a negative correlation between the 
slightly decreasing MRSA-days-associated nosocomial 
MRSA rate and the increasing screening rate. This also 
suggests that in those hospitals where screening was 
performed consistently it was followed by adequate 
hand hygiene, contact precautions, isolation of MRSA-
carriers and subsequently led to a reduction of nosoco-
mial transmissions.
Another important question related to the implemen-
tation of preventive strategies is whether they are 
effective in reducing the number of nosocomial MRSA 
cases. Many authors have investigated this issue with 
divergent results [31,34-36]. In this context, we found 
that from 2009 to 2011 the nosocomial incidence den-
sity decreased significantly from 0.13/1,000 patient 
days to 0.08/1,000 patient days. This indicates that 
after an implementation period, when MRSA carriers 
were detected at an early stage, the rate of nosocomial 
cross-transmission was reduced.
Besides screening, hand hygiene, isolation of MRSA-
carriers and contact precautions the ‘search and fol-
low’-strategy in the EUREGIO implies a post-discharge 
MRSA-case management outside the hospital [15]. In 
this way after a reduction of the nosocomial burden, 
the overall burden of MRSA-carriage in the region may 
be reduced.
This study also has some limitations. Analysis of MRSA-
surveillance data of all hospitals in a regional network 
cannot adjust for all existing differences between the 
hospitals including different specialities, difference 
in the presence of infection control staff, different 
patient populations and case-mixes. Especially in 2007 
and 2008, there were missing data concerning MRSA 
days or classification of MRSA cases as imported or 
nosocomial. We addressed the latter by not calculat-
ing statistical differences in the absolute numbers of 
nosocomial cases, in the MRSA-admission incidence, 
in the nosocomial MRSA incidence density and in 
the MRSA-days-associated nosocomial MRSA rate 
assessed between 2007 and 2008. However, during 
the course of the study, the quality of data collection 
was enhanced and the statistical tests indicated robust 
performance. Furthermore, we cannot adjust for differ-
ences in further hygiene measures implemented in the 
participating hospitals (e.g. different participation in 
the German version of the World Health Organization 
(WHO) campaign ‘Clean Care is Safer Care’ [37]). In the 
future, the network will have to focus on a structured 
assessment of nosocomial MRSA infections rather than 
cases of colonisation and infection to monitor the clini-
cal impact of MRSA.
In conclusion, we documented the successful imple-
mentation of a screening programme in hospitals 
participating in a regional prevention network. This 
approach led to a significant increase of MRSA cases, 
but, eventually to a significant reduction of nosocomial 
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MRSA-cases per 1,000 patient days. The data reflects 
a paradoxical situation (‘MRSA-screening-paradox’): 
Initially, more MRSA carriers are found when more 
patients are screened. This may make some hospitals 
reluctant in establishing such a screening policy due 
to increasing and costly efforts to isolate patients in 
single rooms. However, only after few years, the noso-
comial MRSA burden starts to reduce, which finally 
may encourage the hospitals to accept this burden of 
prevention. Since efforts of single hospitals may not 
change the MRSA-situation in the long run, this argues 
for establishing regional networks of healthcare pro-
viders sharing a common patient catchment population 
and synchronising prevention methods in the net-
works. Within such a network, surveillance data can be 
used for internal benchmarking as well as for valida-
tion and improvement of local standards. Thereby the 
network can support the work of local infection control 
personnel.
Acknowledgements 
The EUREGIO MRSA-net and accordingly the EurSafety 
Health-Net project are financially supported by external 
funding within the community initiative Interreg IIIA/IVA pro-
gramme ‘Germany-Nederland’ of the European Union and 
by the German states of North Rhine-Westphalia and Lower 
Saxony and the Dutch provinces Overijssel, Gelderland 
and Limburg (Reference no. of EUREGIO MRSA-net Twente/
Münsterland: 2-EUR-V-1=96; EurSafety Health-net: (Interreg 
IVa III-1-01=073). We acknowledge all the active participants 
of the EUREGIO MRSA-Net/ EurSafety Health-Net projects: 
The infection control nurses and the physicians responsible 
for infection control of the 40 participating hospitals, the 
participating microbiological laboratories Labor Nordwest 
in Schüttdorf and Labor Münster in Münster, Enzenauer 
Laboratory in Osnabrück, the project representatives ap-
pointed by the public health offices in the EUREGIO, espe-
cially Ms. Scherwinski and Ms. Winkler (both Borken), Dr. 
Toepper (Coesfeld), Dr. Bierbaum (Münster), Dr. Schmeer 
(Steinfurt), Dr. Zaps-Van Aken and Mr. Ziech (Warendorf). We 
would also like to thank Prof. Peters (Institute for Medical 
Microbiology, Münster) and Prof. Karch (Institute of Hygiene, 
Münster), Prof. Harmsen (University of Münster), Dr. 
Lehmann (NRW Institute of Health and Work), Ms. Schmidt 
and Ms. Lunemann (NRW Centre for Health) as well as the 
staff of the regional laboratories participating in the project. 
Moreover, we thank Prof. Mielke and Prof. Witte (both Robert 
Koch-Institute), the Euregional Centre for Health, the Euregio 
Gronau/Enschede and all other direct and indirect partici-
pants for supporting the project activities and their scientific 
advice.
References
1. Köck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth 
S, Kluytmans J, et al. Methicillin-resistant Staphylococcus 
aureus (MRSA): burden of disease and control challenges 
in Europe. Euro Surveill. 2010;15(41):pii=19688. Available 
from: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=19688. PMid:20961515. 
2. de Kraker ME, Davey PG, Grundmann H. Mortality and hospital 
stay associated with resistant Staphylococcus aureus and 
Escherichia coli bacteremia: estimating the burden of antibiotic 
resistance in Europe. PLoS Med. 2011;8(10):e1001104. http://
dx.doi.org/10.1371/journal.pmed.1001104. PMid:22022233. 
PMCid:PMC3191157.
3. European Centre for Disease Prevention and Control/European 
Medicines Agency (ECDC/EMEA). Joint technical report. 
The bacterial challenge: time to react. Stockholm: ECDC/
EMEA; Sep 2009. Available from: http://www.ecdc.europa.
eu/en/publications/Publications/0909_TER_The_Bacterial_
Challenge_Time_to_React.pdf.
4. European Centre for Disease Prevention and Control (ECDC). 
Antimicrobial resistance surveillance in Europe 2010. 
Annual Report on the European Antimicrobial Resistance 
Surveillance Network (EARS-Net). Stockholm: ECDC; 2011. 
Available from: http://www.ecdc.europa.eu/en/publications/
Publications/1111_SUR_AMR_data.pdf.pdf
5. van Cleef BA, Kluytmans JA, van Benthem BH, Haenen A, 
Monen J, Daniels-Haardt I, et al. Cross Border Comparison 
of MRSA Bacteraemia between The Netherlands and North 
Rhine-Westphalia (Germany): A Cross-Sectional Study. PLoS 
One. 2012;7(8):e42787. http://dx.doi.org/10.1371/journal.
pone.0042787. PMid:22880109. PMCid:PMC3411841.
6. NRW Institute of Health and Work (LZG.NRW). 
Infektionsjahresbericht 2010. [Yearly infection report 2010]. 
Bielefeld: LZG.NWR. [Accessed 14 Sep 2012]. German. Available 
from: http://www.lzg.gc.nrw.de/themen/gesundheit_berichte_
daten/infektionsberichte/jahresbericht2010/index.html
7. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt 
BG, Harmsen D, Friedrich AW et al. Geographic distribution 
of Staphylococcus aureus causing invasive infections in 
Europe: a molecular-epidemiological analysis. PLoS Med. 
2010;7(1):e1000215. http://dx.doi.org/10.1371/journal.
pmed.1000215. PMid:20084094. PMCid:PMC2796391.
8. Schaumburg F, Köck R, Mellmann A, Richter L, Hasenberg F, 
Kriegeskorte A, et al. Population Dynamics among Methicillin-
Resistant Staphylococcus aureus Isolates in Germany during 
a 6-Year Period. J Clin Microbiol. 2012;50(10):3186-92. 
http://dx.doi.org/10.1128/JCM.01174-12. PMid:22814464. 
PMCid:PMC3457438.
9. Köck R, Brakensiek L, Mellmann A, Kipp F, Henderikx M, 
Harmsen D, et al. Cross-border comparison of the admission 
prevalence and clonal structure of methicillin-resistant 
Staphylococcus aureus. J Hosp Infect. 2009;71(4):320-6. 
http://dx.doi.org/10.1016/j.jhin.2008.12.001. PMid:19201056.
10. Robotham JV, Scarff CA, Jenkins DR, Medley GF. Meticillin-
resistant Staphylococcus aureus (MRSA) in hospitals and the 
community: model predictions based on the UK situation. J 
Hosp Infect. 2007;65 Suppl 2:93-9. http://dx.doi.org/10.1016/
S0195-6701(07)60023-1
11. Mattner F, Biertz F, Ziesing S, Gastmeier P, Chaberny IF. Long-
term persistence of MRSA in re-admitted patients. Infection. 
2010;38(5):363-71. http://dx.doi.org/10.1007/s15010-010-
0038-8. PMid:20602144. PMCid:PMC2945710.
12. Barnes SL, Harris AD, Golden BL, Wasil EA, Furuno JP. 
Contribution of interfacility patient movement to overall 
methicillin-resistant Staphylococcus aureus prevalence 
levels. Infect Control Hosp Epidemiol. 2011;32(11):1073-
8. http://dx.doi.org/10.1086/662375. PMid:22011533. 
PMCid:PMC3331707.
13. Lee BY, McGlone SM, Wong KF, Yilmaz SL, Avery TR, Song 
Y, et al. Modeling the Spread of Methicillin-Resistant 
Staphylococcus aureus (MRSA) Outbreaks throughout 
the Hospitals in Orange County, California. Infect Control 
Hosp Epidemiol. 2011;32(6):562-72. http://dx.doi.
org/10.1086/660014. PMid:21558768. PMCid:PMC3388111.
14. Ciccolini M, Donker T, Köck R, Mielke M, Hendrix R, Jurke A, et 
al. Infection prevention in a connected world: The case for a 
regional approach. Int J Med Microbiol. 2013;303(6-7):380-7. 
http://dx.doi.org/10.1016/j.ijmm.2013.02.003. PMid:23499307.
15. Friedrich AW, Daniels-Haardt I, Köck R, Verhoeven F, Mellmann 
A, Harmsen D, et al. EUREGIO MRSA-net Twente/Münsterland-
-a Dutch-German cross-border network for the prevention 
and control of infections caused by methicillin-resistant 
Staphylococcus aureus. Euro Surveill. 2008;13(35):pii=18965. 
Available from: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=18965
16. Donker T, Wallinga J, Slack R, Grundmann H. Hospital 
networks and the dispersal of hospital-acquired pathogens 
by patient transfer. PLoS One. 2012;7(4):e35002. http://
dx.doi.org/10.1371/journal.pone.0035002. PMid:22558106. 
PMCid:PMC3338821.
17. Commission for Hospital Hygiene and Infection Prevention 
at the Robert Koch-Institut. Recommendations for the 
prevention and control of methicillin-resistant Staphylococcus 
aureus isolates (MRSA) in hospitals and other healthcare 
facilities. GMS Krankenhhyg Interdiszip. 2009;4(1):Doc01. 
PMid:20204101. PMCid:PMC2831515.
18. Commission for Hospital Hygiene and Infection Prevention at 
the Robert Koch-Institut. Kommentar zu den Empfehlungen 
zur Prävention und Kontrolle von MRSA-Stämmen in 
Krankenhäusern und anderen medizinischen Einrichtungen. 
[Comment on Recommendations for the prevention and control 
of methicillin-resistant Staphylococcus aureus isolates (MRSA) 
9www.eurosurveillance.org
in hospitals and other healthcare facilities]. Epidemiologisches 
Bulletin. 2008;42:363-4. German.
19. Korczak D, Schöffmann C. Medical and health economic 
evaluation of prevention- and control measures related 
to MRSA infections or -colonisations at hospitals. GMS 
Health Technol Assess. 2010;6:Doc04. PMid:21289877. 
PMCid:PMC3010887.
20. Simon A, Exner M, Kramer A, Engelhart S. Implementing 
the MRSA recommendations made by the Commission for 
Hospital Hygiene and Infection Prevention (KRINKO) of 1999 - 
current considerations by the DGKH Management Board. GMS 
Krankenhhyg Interdiszip. 2009;4(1):Doc02. PMid:20204102. 
PMCid:PMC2831514.
21. Eurostat. Regulation (EC) No 1059/2003 of the European 
Parliament and of the council of 26 May 2003 on the 
establishment of a common classification of territorial units 
for statistics (NUTS). [Accessed 02 Sep 2013]. Available from: 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSL
EG:2003R1059:20110207:EN:PDF
22. German National Reference Center for Surveillance of 
Nosocomial Infections (NRZ). [MRSA Reference data 2011 of 
MRSA hospital infection surveillance system (KISS)]. Berlin: 
NRZ. [Accessed 01 Sep 2012]. German. Available from: 
http://www.nrz-hygiene.de/fileadmin/nrz/module/mrsa/
MRSAReferenz2011_stand_20_07_2012.pdf
23. Vos MC, Behrendt MD, Melles DC, Mollema FP, de Groot 
W, Parlevliet G, et al. 5 years of experience implementing 
a methicillin-resistant Staphylococcus aureus search and 
destroy policy at the largest university medical center in the 
Netherlands. Infect Control Hosp Epidemiol. 2009;30(10):977-
84. http://dx.doi.org/10.1086/605921. PMid:19712031. 
24. Friedrich AW. [EUREGIO MRSA-net Twente/Munsterland: 
“’search & follow”’ by Euregional network building]. 
Gesundheitswesen. 2009;71(11):766-70. German. http://dx.doi.
org/10.1055/s-0029-1241892. PMid:19937565. 
25. Salgado CD, Vos MC, Farr BM. Universal screening for 
methicillin-resistant Staphylococcus aureus by hospitals. 
JAMA. 2008;300(5):503-4. http://dx.doi.org/10.1001/
jama.300.5.503-b. PMid:18677019. 
26. German Hospital Society (DKG). [Preliminary key data of 
hospital statistics 2011]. [Accessed 14 Sep 2012]. German. 
Available from: http://www.dkgev.de/media/file/12149.
RS266-12_KH-Statistik-2011_vorlaeufig_A1.pdf
27. Köck R, Mellmann A, Schaumburg F, Friedrich AW, Kipp 
F, Becker K. The Epidemiology of Methicillin-Resistant 
Staphylococcus aureus (MRSA) in Germany. Dtsch Arztebl Int. 
2011;108(45):761-7. PMid:22163252. PMCid:PMC3230165.
28. Chaberny IF, Sohr D, Rüden H, Gastmeier P. Surveillance 
of MRSA over 3 years shows a significant reduction of the 
nosocomial MRSA incidence density – analysis of 26 German 
MRSA-KISS hospitals. J Hosp Infect. 2006;64 Suppl 1:S82. 
http://dx.doi.org/10.1016/S0195-6701(06)60273-9
29. Gastmeier P, Schwab F, Chaberny I, Geffers C. Individual units 
rather than entire hospital as the basis for improvement: the 
example of two Methicillin resistant Staphylococcus aureus 
cohort studies. Antimicrob Resist Infect Control. 2012;1(1):8. 
http://dx.doi.org/10.1186/2047-2994-1-8. PMid:22958320. 
PMCid:PMC3436609.
30. Meyer E, Gastmeier P, Weizel-Kage D, Schwab F. Associations 
between nosocomial meticillin-resistant Staphylococcus 
aureus and nosocomial Clostridium difficile-associated 
diarrhoea in 89 German hospitals. J Hosp Infect. 
2012;82(3):181-6. http://dx.doi.org/10.1016/j.jhin.2012.07.022. 
PMid:23021304.
31. Diller R, Sonntag AK, Mellmann A, Grevener K, Senninger 
N, Kipp F, et al. Evidence for cost reduction based on pre-
admission MRSA screening in general surgery. Int J Hyg Environ 
Health. 2008;211(1-2):205-12. http://dx.doi.org/10.1016/j.
ijheh.2007.06.001. PMid:17692566.
32. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost 
analysis of a hospital-wide selective screening programme for 
methicillin-resistant Staphylococcus aureus (MRSA) carriers 
in the context of diagnosis related groups (DRG) payment. Clin 
Microbiol Infect. 2005;11(6):466-71. http://dx.doi.org/10.1111/
j.1469-0691.2005.01153.x. PMid:15882196.
33. Gastmeier P, Chaberny IF. [Which rate describes the 
MRSA situation appropriately]? Dtsch med Wochenschr. 
2007;132(27):1480-2. German. http://dx.doi.
org/10.1055/s-2007-982056. PMid:17583833.
34. Camus C, Bellissant E, Legras A, Renault A, Gacouin A, Lavoué 
S, et al. Randomized comparison of 2 protocols to prevent 
acquisition of methicillin-resistant Staphylococcus aureus: 
results of a 2-center study involving 500 patients. Infect 
Control Hosp Epidemiol. 2011;32(11):1064-72. http://dx.doi.
org/10.1086/662180. PMid:22011532. 
35. Harbarth S, Fankhauser C, Schrenzel J, Christenson J, 
Gervaz P, Bandiera-Clerc C, et al. Universal screening for 
methicillin-resistant Staphylococcus aureus at hospital 
admission and nosocomial infection in surgical patients. 
JAMA. 2008;299(10):1149-57. http://dx.doi.org/10.1001/
jama.299.10.1149. PMid:18334690. 
36. Harbarth S, Masuet-Aumatell C, Schrenzel J, Francois P, 
Akakpo C, Renzi G, et al. Evaluation of rapid screening and 
pre-emptive contact isolation for detecting and controlling 
methicillin-resistant Staphylococcus aureus in critical care: 
an interventional cohort study. Crit Care. 2006;10(1):R25. 
http://dx.doi.org/10.1186/cc3982. PMid:16469125. 
PMCid:PMC1550853.
37. World Health Organization (WHO). Clean Care is Safer Care. 
Geneva: WHO. [Accessed 21 Aug 2013]. Available from: http://
www.who.int/gpsc/en/
